Clinical trials: Early Breast Cancer, open to volunteers
HR+/HER2- Early Breast Cancer
Evaluating the Effectiveness of Typology-based Coaching on Patients' Therapy Management
The goal of this clinical trial is to evaluate the effect of patient education and patient typology-based coaching on therapy persistence in breast cancer patients taking ribociclib.
- Trial name
- TYPER (NCT07708571)
- Testing
- Typology-based coaching
- Where
- 3 sites in Germany
- Volunteers
- 548 people
- Sponsor
- Institut fuer Frauengesundheit
Hormone Receptor-Positive Breast Cancer, High-risk Breast Cancer
ctDNA-Guided De-Escalation of Adjuvant Chemotherapy With Dalpiciclib in HR-Positive/HER2-Negative Breast Cancer
This is a Phase II, multicenter, randomized clinical trial evaluating a ctDNA-guided approach to de-escalate adjuvant chemotherapy in patients with hormone receptor (HR)-positive, HER2-negative early-stage breast cancer.
- Conditions
- Hormone Receptor-Positive Breast Cancer, High-risk Breast Cancer, Early-Stage Breast Cancer, HER2-negative Breast Cancer
- Trial name
- DNADalHR (NCT06970912)
- Testing
- Dalpiciclib + Aromatase Inhibitor with ctDNA-Guided Therapy, Taxane-Based Neoadjuvant Chemotherapy
- Where
- China
- Volunteers
- 393 people
- Sponsor
- Peking University People's Hospital
Hormone Receptor-Positive Breast Cancer, High-risk Breast Cancer
CDK4/6 Inhibitors Combined With Endocrine Therapy for Neoadjuvant Treatment
Exploring the dynamics of ctDNA following neoadjuvant therapy with CDK4/6 inhibitors combined with endocrine treatment, and its potential to guide de-escalation of adjuvant chemotherapy
- Conditions
- Hormone Receptor-Positive Breast Cancer, High-risk Breast Cancer, Early-Stage Breast Cancer, HER2-negative Breast Cancer
- Trial name
- DNACDKHR (NCT07366112)
- Testing
- CDK4/6 inhibitor with endocrine therapy
- Where
- China
- Volunteers
- 158 people
- Sponsor
- Peking University People's Hospital
Cancer, Breast Cancer Early Stage Breast Cancer (Stage 1-3)
Advancing Care Coordination Between Cancer and Primary Care Teams for Complex Cancer Survivors
The purpose of this randomized clinical trial is to learn if 'complex' cancer patients who receive care guided by a health system intervention, Primary Care Connect (PC2) have their risks of cardiovascular disease (CVD) managed…
- Conditions
- Cancer, Breast Cancer Early Stage Breast Cancer (Stage 1-3), Bladder Cancer, Prostate Cancer (Adenocarcinoma)
- Trial name
- ACCESS-PC (NCT06834204)
- Testing
- PC2: Primary Care Connect
- Where
- United States
- Volunteers
- 266 people
- Sponsor
- Rutgers, The State University of New Jersey
Early-stage Breast Cancer
Evaluating Omission of Granulocyte Colony-stimulating Factors in Breast Cancer Patients Receiving Paclitaxel Portion of Dose-dense Adriamycin-cyclophosphamide and Paclitaxel Chemotherapy
The goal of this randomized, pragmatic clinical trial is to evaluate the omission of granulocyte colony-stimulating factors (G-CSF) in breast cancer patients receiving paclitaxel portion of dose-dense adriamycin-cyclophosphamide…
- Trial name
- REaCT-OGF (NCT05753618)
- Testing
- Granulocyte Colony-Stimulating Factor (G-CSF), Omission of Granulocyte Colony-Stimulating Factor (G-CSF)
- Where
- 3 sites in Canada
- Volunteers
- 242 people
- Sponsor
- Ottawa Hospital Research Institute
Hormone-receptor-positive Breast Cancer, Early Breast Cancer
Clinical Study of Local and Systemic Biological Impact of GLP1/GIP-Receptor Agonists in Patients With Breast Cancer: The CLARA Trial
The CLARA trial is a phase II window-of-opportunity trial evaluating how a commonly used weight-loss medication (tirzepatide, a GLP-1/GIP receptor agonist) affects breast cancer biology, alone and in combination with standard…
- Trial name
- CLARA (NCT07676331)
- Testing
- Tirzepatide, Letrozole (Aromatase Inhibitors)
- Volunteers
- 168 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
HR+/HER2- Early Breast Cancer
RWE Non-Interventional Prospective Study of Ribociclib Effectiveness and Safety in Patients With HR+/HER2- Early Breast Cancer in Saudi Arabia
This is a non-interventional, prospective, single-arm, observational study describing the real-world effectiveness, safety, and PRO and HCRU data of ribociclib combined with adjuvant ET under conditions of routine clinical…
- Trial name
- NISLEESA (NCT06797531)
- Testing
- ribociclib
- Where
- 2 sites in Saudi Arabia
- Volunteers
- 177 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer Invasive, Early-stage Breast Cancer
BRE-04: Window of Opportunity Trial of Preoperative Low Dose Azacitidine in High-Risk Early Stage Breast Cancer
To determine the effect of low dose azacitidine therapy on tumor infiltrating lymphocytes (TILs) in primary tumors from patients with high-risk early stage breast cancer, paired t-tests will be first used to compare TIL count in…
- Conditions
- Breast Cancer Invasive, Early-stage Breast Cancer, High Risk Breast Carcinoma
- Trial name
- BRE-04 (NCT04891068)
- Testing
- Azacitidine
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Illinois at Chicago
Early Stage Breast Carcinoma, Breast Cancer
Risk-Stratified Hypofractionated Radiotherapy After Breast-Conserving Surgery for Early Breast Cancer
This prospective study is designed to evaluate the feasibility, efficacy, and safety of risk-stratified hypofractionated radiotherapy after breast-conserving surgery in patients with early breast cancer.
- Trial name
- NCT07657442
- Testing
- Whole-breast irradiation and tumor bed boost, Partial-breast irradiation
- Where
- China
- Volunteers
- 649 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Mammogram Uptake, Breast Cancer
Trial to Evaluate the Impact of Various Pragmatic Interventions to Increase Mammography Uptake Among Defaulted Repeat Screeners in Singapore
Breast cancer is the most common cancer among women in Singapore, accounting for nearly 30% of all female cancers. While regular biennial mammography can reduce mortality, screening rates in Singapore remain low at 34.7%; well…
- Conditions
- Mammogram Uptake, Breast Cancer, Breast Neoplasm, Early Detection of Cancer
- Trial name
- REMIND1 (NCT07651345)
- Testing
- Arm 2: One mailed reminder, Arm 3: Two mailed reminders, Arm 4: Mailed reminder with prescheduled appointment
- Where
- Singapore
- Volunteers
- 12,750 people, healthy volunteers welcome
- Sponsor
- National University Hospital, Singapore
Cardiovascular Health, Breast Cancer
JUdicious Surveillance for Trastuzumab Induced Cardiotoxicity in the First Year
This study focuses on male and female patients being treated for breast cancer that is positive for the HER2 receptor which requires special treatments targeting that receptor.
- Conditions
- Cardiovascular Health, Breast Cancer, Breast Cancer Early Stage Breast Cancer (Stage 1-3), Cardio-oncology
- Trial name
- JUSTIFY (NCT06930521)
- Testing
- Intervention - Low Risk Group OR Intermediate Risk Group
- Where
- Canada
- Volunteers
- 300 people
- Sponsor
- Women's College Hospital
Geriatric Assessment, Adjuvant Drug Therapy
Aspects of Adjuvant CDK4/6 Inhibitors in Older Breast Cancer Patients - Focusing on Geriatric Screening
Older breast cancer patients should not be categorically excluded from adjuvant therapies, including the recommended CDK4/6 inhibitors (CDK4/6i) administered in combination with endocrine therapy.
- Conditions
- Geriatric Assessment, Adjuvant Drug Therapy, Breast Cancer Early Stage Breast Cancer (Stage 1-3)
- Trial name
- FUTURE (NCT07273357)
- Where
- 5 sites in Sweden
- Volunteers
- 200 people
- Sponsor
- Region Jönköping County
HER2-positive Early Breast Cancer
NeoAdjuvant Therapy With Trastuzumab-deruxtecan Versus Chemotherapy+Trastuzumab+Pertuzumab in HER2+ Early Breast Cancer
ADAPT-HER2-IV will address question of optimal neoadjuvant therapy in patients with less advanced -HER2+ EBC. ADAPT-HER2-IV is planned as a superiority trial to demonstrate higher pCR rates in both clinically relevant subgroups…
- Trial name
- ADAPTHER2-IV (NCT05704829)
- Testing
- Trastuzumab deruxtecan, Standard-of-Care
- Where
- 44 sites in Germany
- Volunteers
- 702 people
- Sponsor
- Women's Cancer Study Group GmbH
Breast Cancer, Early Detection of Cancer
Strategies to Decentralize Breast Ultrasound in Rwanda
Diagnosing breast cancer early is critical to reduce preventable breast cancer deaths in sub-Saharan Africa. This can be done in part through increasing patients' access to breast ultrasound, which is essential for evaluating…
- Conditions
- Breast Cancer, Early Detection of Cancer, Ultrasonography
- Trial name
- NCT06812208
- Testing
- Teleultrasound with Philips Lumify ultrasound probes and Reacts software, Asynchronous virtual feedback
- Where
- Rwanda
- Volunteers
- 1,792 people, healthy volunteers welcome
- Sponsor
- Brigham and Women's Hospital
Breast Cancer Early Stage Breast Cancer (Stage 1-3)
FLASH-Breast: Evaluating the Efficacy of Fezolinetant in Reducing Vasomotor Symptoms in Women With Breast Cancer on Endocrine Therapy
This is a phase II, randomized, double-blinded, placebo-controlled trial designed to evaluate the efficacy of fezolinetant (45 mg a day) vs.
- Trial name
- NCT06917313
- Testing
- Fezolinetant
- Where
- 2 sites in United States
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- Yale University
HR+/HER2+ Early Breast Cancer
Fovinaciclib Plus Aromatase Inhibitors and Dual HER2 Blockade in a Response-Adapted Neoadjuvant Strategy for HR-Positive/HER2-Positive Early Breast Cancer
This prospective, response-adapted phase II study evaluates the efficacy and safety of neoadjuvant fovinaciclib in combination with aromatase inhibitors and dual HER2 blockade in patients with HR-positive/HER2-positive early…
- Trial name
- TAYLOR-003 (NCT07616427)
- Testing
- Fovinaciclib, Aromatase Inhibitors, Trastuzumab + Pertuzumab
- Where
- 3 sites in China
- Volunteers
- 100 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
HR+/HER2- Early Breast Cancer
Efficacy and Safety of Culmerciclib Plus Aromatase Inhibitors in a Response-Adapted Neoadjuvant Strategy for Highly Proliferative ER-Positive/HER2-Negative Breast Cancer
This prospective, response-adapted phase II study evaluates the efficacy and safety of neoadjuvant culmerciclib in combination with aromatase inhibitors in patients with highly proliferative ER-positive/HER2-negative breast…
- Trial name
- TAYLOR-002 (NCT07616453)
- Testing
- Culmerciclib, Aromatase Inhibitors
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Breast Neoplasm, Breast Cancer
Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy
The purpose of this study is to establish a prospective, single-center platform research based on clinical subtypes to explore precision neoadjuvant therapy in patients with operable breast cancer who met the indications for…
- Conditions
- Breast Neoplasm, Breast Cancer, Breast Tumors, Triple-Negative Breast Cancer (TNBC)
- Trial name
- FASCINATE-N (NCT05582499)
- Testing
- Dalpiciclib, Pyrotinib, SHR-A1811
- Where
- China
- Volunteers
- 716 people
- Sponsor
- Fudan University
Breast Cancer Early Stage Breast Cancer (Stage 1-3)
Video-Conferenced Stress Management and Relaxation Training (VSMART) For Alabama Breast Cancer Survivors
In a sample of Alabama breast cancer survivors, the proposed study tests the feasibility and acceptability of a stress management program that has been shown to improve health and wellbeing in a general population of patients…
- Trial name
- VSMART (NCT06924788)
- Testing
- Video-Conferenced Stress Management and Relaxation Training (VSMART)
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Alabama at Birmingham
Breast Cancer Early Stage Breast Cancer (Stage 1-3)
ON-treatment Single-cell Analysis for the Identification of Early Tumor Response Biomarkers on Prospective Collected Serial Tumor Biopsies in Triple Negative Breast Cancer Patient During Standard Neoadjuvant Chemo-immunotherapy
This study explores early breast cancer, focusing on triple-negative and high-risk luminal subtypes. It combines single-cell RNA sequencing and spatial imaging of tumor samples collected at different time points during treatment.
- Trial name
- ONSET (NCT07597642)
- Testing
- on treatment biopsy (after C1)
- Where
- Italy
- Volunteers
- 55 people
- Sponsor
- IRCCS San Raffaele